Pheast Therapeutics’ PHST001, targeting CD24 to enhance immune response against tumors, received FDA Fast Track Designation for ovarian cancer treatment. CD24, a cell surface protein identified as a macrophage checkpoint, hinders cancer cell clearance by engaging Siglec-10, an inhibitory receptor on macrophages. This discovery by Dr. Amira Barkal and team at Pheast promises a novel […]
Category: Fast Track Designation
Rina-S Shows 50% Response Rate for Advanced Endometrial Cancer
In a study on advanced endometrial cancer, patients were administered either 100 mg/m2 (22 patients) or 120 mg/m2 (42 patients) of Rina-S. The confirmed overall response rate was 50% in the 100 mg/m2 group, with two complete responses. For the 120 mg/m2 group, the confirmed response rate was 47.1%, indicating anti-tumor activity. The median duration […]
